模拟禁食饮食用于轻中度克罗恩病患者:一项随机对照试验
这项开放标签随机对照试验评估模拟禁食饮食(FMD)对轻中度克罗恩病成人的效果。FMD组每月连续5天执行FMD、连续3个月,非FMD日恢复基线饮食;对照组继续基线饮食。FMD组临床应答率69.2% vs 对照组43.8%(P=0.03),临床缓解率64.6% vs 37.5%(P=0.02),粪便钙卫蛋白较基线变化-22.0% vs 8.0%(P=0.03)。
要点
- FMD组临床应答69.2%,对照组43.8%(P=0.03)。
- FMD组临床缓解64.6%,对照组37.5%(P=0.02)。
- 粪便钙卫蛋白较基线变化FMD组-22.0% vs 对照组8.0%(P=0.03)。
核心结论
- FMD在诱导轻中度克罗恩病临床应答、临床缓解和生化改善方面优于基线饮食。
- 作者支持进一步研究FMD作为慢性炎症性疾病的辅助治疗。
研究设计与样本
- 开放标签随机对照试验,纳入轻中度克罗恩病成人。
- FMD组每月连续5天执行FMD、连续3个月,非FMD日恢复基线饮食;对照组继续基线饮食。
- 主要结局为第3个5天饮食周期后CDAI降低至少70分或CDAI≤150的临床应答。
主要发现
- FMD组45例(69.2%)vs 对照组14例(43.8%)达到临床应答(P=0.03)。
- FMD组42例(64.6%)vs 对照组12例(37.5%)达到临床缓解(P=0.02)。
- 粪便钙卫蛋白较基线变化:FMD组-22.0% vs 对照组8.0%(P=0.03)。
- 探索性分析显示FMD后关键炎症脂质介质和外周血单核细胞免疫效应转录本下降,与CD活动度降低一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In healthy individuals, short cycles of a fasting-mimicking diet (FMD) decrease systemic inflammatory markers and improve metabolic health. Potential benefits of FMD have not been investigated in Crohn's disease (CD). We conducted an open-label, randomized, controlled trial to assess the effects of FMD in adults with mild-to-moderate CD. Patients in the FMD group followed an FMD for five consecutive days per month for three consecutive months, returning to their regular baseline diet on non-FMD days. Control participants continued their baseline diet. The primary outcome of clinical response was a reduction in CD Activity Index (CDAI) of at least 70 points or CDAI of ≤150 after the third 5-day diet cycle. Forty-five patients in the FMD group (69.2%) and 14 patients in the control group (43.8%) met the primary outcome of clinical response (P = 0.03). Forty-two patients in the FMD group (64.6%) and 12 patients in the control group (37.5%) achieved the secondary outcome of clinical remission (P = 0.02). There was also a decline from baseline in fecal calprotectin (an inflammatory marker) in the FMD group compared with the control group (-22.0% versus 8.0%, P = 0.03). Exploratory analyses of plasma metabolites and peripheral blood mononuclear cell gene expression revealed post-FMD decreases in key inflammatory lipid mediators and immune-effector transcripts, concordant with reduced CD activity. Together, these findings demonstrate that FMD is superior to a baseline diet for inducing clinical response, clinical remission and biochemical improvement in mild-to-moderate CD, and support further investigation of FMD as an adjunctive therapy for chronic inflammatory diseases. ClinicalTrials.gov registration: NCT04147585 .
引用
- Kulkarni C, Fardeen T, Gubatan J, et al. A fasting-mimicking diet in patients with mild-to-moderate Crohn's disease: a randomized controlled trial. Nat Med. 2026. PMID: 41530382. doi:10.1038/s41591-025-04173-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。